［1］ MILLER KD,NOGUEIRA L,MARIOTTO AB,et al.Cancer treatment and survivorship statistics,2019［J］.CA:A Cancer Journal For Clinicians,2019,69(5):363-385.
［2］ HAMID O,COWEY CL,OFFNER M,et al.Efficacy,safety,and tolerability of approved combination BRAF and MEK inhibitor regimens for BRAF-mutant melanoma［J］.Cancers (Basel),2019,11(11):1642.
［3］ SAGINAL AK,BARSOUK A,ALURU JS,et al.Epidemiology of melanoma［J］.Med Sci (Basel),2021,9(4):63.
［4］ WANG B,ZHANG W,ZHANG G,et al.Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma［J］.Oncogene,2021,40(37):5590-5599.
［5］ HAAS L,ELEWAUT A,GERARD CL,et al.Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy in melanoma［J］.Nat Cancer,2021,2(7):693-708.
［6］ JAMAL SME,ALAMODI A,WAHL RU,et al.Melanoma stem cell maintenance and chemo-resistance are mediated by CD133 signal to PI3K-dependent pathways［J］.Oncogene,2020,39(32):5468-5478.
［7］CANDIDO S,SALEMI R,PICCININ S,et al.The PIK3CA H1047R mutation confers resistance to BRAF and MEK inhibitors in A375 melanoma cells through the cross-activation of MAPK and PI3K-AKt pathways［J］.Pharmaceutics,2022,14(3):590.
［8］ZHAO Y,JIN LJ,ZHANG XY.Exosomal miRNA-205 promotes breast cancer chemoresistance and tumorigenesis through E2F1［J］.Aging (Albany NY),2021,13(14):18498-18514.
［9］YU S,ZHOU Y,NIU L,et al.Mesenchymal stem cell-derived exosome miR-342-3p inhibits metastasis and chemo-resistance of breast cancer through regulating ID4［J］.Genes Genomics,2022,44(5):539-550.
［10］ KIM DH,PARK H,CHOI YJ,et al.Exosomal miR-1260b derived from non-small cell lung cancer promotes tumor metastasis through the inhibition of HIPK2［J］.Cell Death Dis,2021,12(8):747.
［11］WANG H,HUANG H,WANG L,et al.Cancer-associated fibroblasts secreted miR-103a-3p suppresses apoptosis and promotes cisplatin resistance in non-small cell lung cancer［J］.Aging (Albany NY),2021,13(10):14456-14468.
［12］XIONG J,HE X,XU Y,et al.MiR-200b is upregulated in plasma-derived exosomes and functions as an oncogene by promoting macrophage M2 polarization in ovarian cancer［J］.J Ovarian Res,2021,14(1):74.
［13］LI T,LIN L,LIU Q,et al.Exosomal transfer of miR-429 confers chemoresistance in epithelial ovarian cancer［J］.Am J Cancer Res,2021,11(5):2124-2141.
［14］KALLURI R,LEBLEU VS.The biology,function,and biomedical applications of exosomes［J］.Science,2020,367(6478):eaau6977.
［15］FABIAN MR,SONENBERG N,FILIPOWICZ W.Regulation of mRNA translation and stability by microRNAs［J］.Annu Rev Biochem,2010,79(1):351-379.
［16］WANG Z,LIU Y.MicroRNA-633 enhances melanoma cell proliferation and migration by suppressing KAI1［J］.Oncol Lett,2021,21(2):88.
［17］DA CRUZ AT,HUNGER A,DE MELO FHM,et al.MiR-138-5p induces aggressive traits by targeting trp53 expression in murine melanoma cells,and correlates with poor prognosis of melanoma patients［J］.Neoplasia,2021,23(8):823-834.
［18］TUPONE MG,D'AGUANNO S,DI MARTILE M,et al.MicroRNA-378a-5p is a novel positive regulator of melanoma progression［J］.Oncogenesis,2020,9(2):22.
［19］SAHOO A,SAHOO SK,JOSHI P,et al.MicroRNA-211 loss promotes metabolic vulnerability and BRAF inhibitor sensitivity in melanoma［J］.J Invest Dermatol,2019,139(1):167-176.
［20］LEE B,SAHOO A,SAWADA J,et al.MicroRNA-211 modulates the DUSP6-ERK5 signaling axis to promote BRAF(V600E)-driven melanoma growth in vivo and BRAF/MEK inhibitor resistance［J］.J Invest Dermatol,2021,141(2):385-394.
［21］GRZYWA TM,KLICKA K,PASKAL W,et al.MiR-410-3p is induced by vemurafenib via ER stress and contributes to resistance to BRAF inhibitor in melanoma［J］.Plos One,2020,15(6):e0234707.
［22］MASSAGUE J,GANESH K.Metastasis-initiating cells and ecosystems［J］.Cancer Discov,2021,11(4):971-994.
［23］GANESH K,MASSAGUE J.Targeting metastatic cancer［J］.Nat Med,2021,27(1):34-44.
［24］PEGTEL DM,GOULD SJ.Exosomes［J］.Annu Rev Biochem,2019,88(1):487-514.
［25］MORAD G,CARMAN CV,HAGEDORN EJ,et al.Tumor-derived extracellular vesicles breach the intact blood-brain barrier via transcytosis［J］.ACS Nano,2019,13(12):13853-13865.
［26］BANKS WA,SHARMA P,BULLOCK KM,et al.Transport of extracellular vesicles across the blood-brain barrier:brain pharmacokinetics and effects of inflammation［J］.Int J Mol Sci,2020,21(12):4407.
［27］WANG P,WU Y,CHEN W,et al.Malignant melanoma-derived exosomes induce endothelial damage and glial activation on a human BBB chip model［J］.Biosensors (Basel),2022,12(2):89.
［28］LI J,CHEN J,WANG S,et al.Blockage of transferred exosome-shuttled miR-494 inhibits melanoma growth and metastasis［J］.J Cell Physiol,2019,234(9):15763-15774.
［29］JACOB A,PREKERIS R.The regulation of MMP targeting to invadopodia during cancer metastasis［J］.Front Cell Dev Biol,2015,3:4.
［30］JABLONSKA TRYPUC A,MATEJCZYK M,ROSOCHACKI S.Matrix metalloproteinases (MMPs),the main extracellular matrix (ECM) enzymes in collagen degradation,as a target for anticancer drugs［J］.J Enzyme Inhib Med Chem,2016,31(sup1):177-183.
［31］李豪,马雪辉,段乳侠,等.黑色素瘤细胞外泌体对成纤维细胞侵袭和MMP2、MMP9表达的影响［J］.陆军军医大学学报,2020,42(08):822-829.
LI H,MA XH,DUAN RX,et al.Effects of melanoma cell exosomes on fibroblast invasion and expression of MMP2 and MMP9 in vitro ［J］.Journal of Army Medical University,2020,42(08):822-829.
［32］WANG C,WANG Y,CHANG X,et al.Melanoma-derived exosomes endow fibroblasts with an invasive potential via miR-21 target signaling pathway［J］.Cancer Manag Res,2020,12:12965-12974.
［33］COX TR.The matrix in cancer［J］.Nat Rev Cancer,2021,21(4):217-238.
［34］UNTIVEROS G,DEZI L,GILLETTE M,et al.Normal skin cells increase aggressiveness of cutaneous melanoma by promoting epithelial-to-mesenchymal transition via nodal and wnt activity［J］.Int J Mol Sci,2021,22(21):11719.
［35］XIAO DY,BARRY S,KMETZ D,et al.Melanoma cell-derived exosomes promote epithelial-mesenchymal transition in primary melanocytes through paracrine/autocrine signaling in the tumor microenvironment［J］.Cancer Letters,2016,376(2):318-327.
［36］LUAN WK,DING YT,XI HL,et al.Exosomal miR-106b-5p derived from melanoma cell promotes primary melanocytes epithelial-mesenchymal transition through targeting EphA4［J］.Journal of Experimental & Clinical Cancer Research,2021,40(1):107.
［37］LIU Y,CAO X.Characteristics and significance of the pre-metastatic niche［J］.Cancer Cell,2016,30(5):668-681.
［38］PEINADO H,KOVIC MA,LAVOTSHKIN S,et al.Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET (vol 18,pg 883,2012)［J］.Nature Medicine,2016,22(12):1502.
［39］SHU S,YANG Y,ALLEN CL,et al.Metabolic reprogramming of stromal fibroblasts by melanoma exosome microRNA favours a pre-metastatic microenvironment［J］.Sci Rep,2018,8(1):12905.
［40］GENER LAHAV T,ADLER O,ZAIT Y,et al.Melanoma-derived extracellular vesicles instigate proinflammatory signaling in the metastatic microenvironment［J］.Int J Cancer,2019,145(9):2521-2534.
［41］ZHOU X,YAN T,HUANG C,et al.Melanoma cell-secreted exosomal miR-155-5p induce proangiogenic switch of cancer-associated fibroblasts via SOCS1/JAK2/STAT3 signaling pathway［J］.J Exp Clin Cancer Res,2018,37(1):242.
［42］ LIU D.Exosomal microRNA-4535 of melanoma stem cells promotes metastasis by inhibiting autophagy pathway［J/OL］.Stem Cell Reviews & Reports,2022,3(17):8［2022-02-23］.https://link.springer.com/article/10.1007/s12015-022-10358-4.DOI:10.1007/s12015-022-10358-4.
［43］LEE B,SAHOO A,SAWADA J,et al.MicroRNA-211 modulates the DUSP6-ERK5 signaling axis to promote BRAF(V600E)-driven melanoma growth in vivo and BRAF/MEK inhibitor resistance［J］.Journal of Investigative Dermatology,2021,141(2):385-394.
［44］FELICETTI F,DE FEO A,COSCIA C,et al.Exosome-mediated transfer of miR-222 is sufficient to increase tumor malignancy in melanoma［J］.Journal of Translational Medicine,2016,14(1):1-15.
［45］LUNAVAT TR,CHENG L,EINARSDOTTIR BO,et al.BRAF(V600) inhibition alters the microRNA cargo in the vesicular secretome of malignant melanoma cells［J］.Proc Natl Acad Sci U S A,2017,114(29):E5930-E5939.
［46］NAJEM A,KRAYEM M,PERDRIX A,et al.New drug combination strategies in melanoma:current status and future directions［J］.Anticancer Research,2017,37(11):5941-5953.
［47］ZHAO H,HAN L,JIAN Y,et al.Resveratrol induces apoptosis in human melanoma cell through negatively regulating Erk/PKM2/Bcl-2 axis［J］.Onco Targets and Therapy,2018,11:8995-9006.